The Rockefeller Foundation awarded to the GISAID Initiative its single largest grant to date, in support of accelerating the advancement of its pathogen data sharing platform. The grant aids in the modernization of the platform to further incentivize the global community of data producers to rapidly share data to enable real-time responses and the development of lifesaving countermeasures. Rockefeller Foundation
During the first year of the coronavirus pandemic, GISAID’s global operations and technical development benefited from public in-kind contributions and grants, in addition to generous donations from private and corporate philanthropy.
GISAID is a partner in the PREDEMICS consortium (Preparedness, Prediction and Prevention of Emerging Zoonotic Viruses with Pandemic Potential using Multidisciplinary Approaches) and leader of WP4 on “Sharing Platforms” to provide software to accommodate the development of databases for three other PREDEMICS viruses: Flaviviruses, Lyssaviruses and Hepeviruses, in addition to Influenza viruses. PREDEMICS
APHL awarded a grant to GISAID under the Enhancing Communication and Information Sharing among International Influenza Networks project, for the development of data-routing technology, enabling GISAID users to provide selected metadata in real-time to other international platforms, advancing the standardization of metadata and the sharing and interpretation of NGS data; and the further development of software for the annotation of phylogenetic trees. APHL
Funding was awarded to GISAID for the enhancement of GISAID’s database application through the Max-Planck-Society and its Max-Planck-Institute for Informatics in Saarbrücken, responsible for the development of GISAID’s EpiFlu™ database v1.0.
The Swiss State Secretariat for Education, Research and Innovation (SERI) and the Federal Office of Public Health (FOPH), provided initial funding for the development of the first EpiFlu™ database application, citing Switzerland's long-standing tradition of neutrality and the presence of the World Health Organization in Geneva and the Lausanne-based biotech company SmartGene. SERI FOPH
The DHHS provided the first public funding to GISAID to kickstart the development of GISAID's EpiFlu™ database application, through a cooperative agreement with the World Health Organization. One of the key goals that was achieved was the timely sharing of data among the WHO Collaborating Centers and National Influenza Centers for the bi-annual influenza vaccine virus recommendations by the WHO Global Influenza Surveillance and Response System (GISRS).